Newsroom
IntelliGenome Receives INVIMA Approval for CRISPR-TB Blood Test and Appoints Velez Lab as Exclusive
IntelliGenome, Inc. has announced that Colombia's National Institute for Food and Drug Surveillance (INVIMA) has granted sanitary registration for the CRISPR-TB Blood Test Kit, enabling commercialization of the test in Colombia.
IntelliGenome Announces Strategic Partnership with CTR Scientific to Advance CRISPR-TB in Mexico
IntelliGenome, Inc. has announced a strategic partnership with CTR Scientific (Control Técnico y Representaciones S.A. de C.V.) to support the evaluation, commercialization, and future adoption of the CRISPR-TB Blood Test in Mexico.
Intelligenome Expands APAC Presence with Establishment of Hangzhou Intelligenome Biotechnology Co.,
Intelligenome has established Hangzhou Intelligenome Biotechnology Co., Ltd., a wholly owned company that marks an important step in expanding the company’s presence and support across APAC. This milestone reflects Intelligenome’s continued commitment to advancing molecular diagnostic research, supporting global collaboration, and working with regional partners to address persistent diagnostic gaps in tuberculosis and beyond.
Intelligenome Announces R&D Subaward Agreement with Cornell University
Intelligenome, a global leader in CRISPR-based in vitro diagnostic (IVD) technology, is pleased to announce that it has entered into a research and development subaward agreement with Cornell University to support the development of a rapid, low-cost, portable diagnostic solution for tuberculosis (TB).
IntelliGenome Receives FDA Breakthrough Device Designation for CRISPR-TB Blood Test
IntelliGenome, an innovative molecular diagnostic solutions provider, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its CRISPR-Tuberculosis (TB) Blood Test.
